NASCIMBENI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.487
EU - Europa 3.521
AS - Asia 3.373
SA - Sud America 602
AF - Africa 78
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.389
SG - Singapore 1.085
GB - Regno Unito 996
CN - Cina 986
IT - Italia 819
HK - Hong Kong 567
BR - Brasile 475
SE - Svezia 343
DE - Germania 312
PL - Polonia 259
VN - Vietnam 254
RU - Federazione Russa 170
UA - Ucraina 101
FR - Francia 100
FI - Finlandia 98
TR - Turchia 98
KR - Corea 86
BG - Bulgaria 68
IN - India 66
NL - Olanda 60
AR - Argentina 55
ID - Indonesia 55
CA - Canada 45
ZA - Sudafrica 32
JP - Giappone 31
LT - Lituania 31
MX - Messico 30
BD - Bangladesh 28
IE - Irlanda 25
BE - Belgio 22
ES - Italia 21
EC - Ecuador 20
RO - Romania 20
IQ - Iraq 15
PK - Pakistan 15
VE - Venezuela 15
AT - Austria 14
CH - Svizzera 14
EG - Egitto 14
CZ - Repubblica Ceca 13
AU - Australia 12
UZ - Uzbekistan 11
CO - Colombia 9
PY - Paraguay 9
MY - Malesia 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
KE - Kenya 7
PE - Perù 7
PH - Filippine 7
IL - Israele 6
IR - Iran 6
JO - Giordania 6
MK - Macedonia 6
AZ - Azerbaigian 5
RS - Serbia 5
UY - Uruguay 5
CL - Cile 4
DZ - Algeria 4
HN - Honduras 4
SI - Slovenia 4
BO - Bolivia 3
CR - Costa Rica 3
EE - Estonia 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
MA - Marocco 3
TW - Taiwan 3
AL - Albania 2
BB - Barbados 2
BZ - Belize 2
EU - Europa 2
GE - Georgia 2
GH - Ghana 2
HR - Croazia 2
KZ - Kazakistan 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CU - Cuba 1
DK - Danimarca 1
GD - Grenada 1
HU - Ungheria 1
Totale 16.061
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Ashburn 830
Santa Clara 816
Singapore 680
Southend 620
Woodbridge 557
Hong Kong 552
Chandler 470
Seattle 451
Houston 450
Wilmington 402
Cambridge 348
Hefei 330
Ann Arbor 317
Nyköping 268
Warsaw 253
Dearborn 236
London 206
Beijing 178
Los Angeles 142
New York 142
Jacksonville 119
Modena 118
Chicago 88
San Diego 81
Seoul 69
Ho Chi Minh City 67
Sofia 66
Princeton 65
Hanoi 64
Eugene 62
Helsinki 61
Milan 60
Munich 56
Council Bluffs 54
Izmir 54
Rome 54
Jakarta 46
Moscow 45
São Paulo 42
Buffalo 41
Dallas 41
The Dalles 41
Shanghai 40
Denver 38
Salt Lake City 30
Bremen 25
Poplar 25
Tokyo 25
Redwood City 24
Johannesburg 23
Fremont 22
Nuremberg 22
Dublin 21
Brussels 20
Biên Hòa 19
Bologna 19
Tampa 19
Columbus 18
Redondo Beach 18
Toronto 18
Atlanta 17
Chennai 17
Frankfurt am Main 17
Haiphong 17
San Mateo 17
Brooklyn 16
Dong Ket 16
Orem 16
Padova 16
Reggio Emilia 16
Stockholm 16
Boardman 15
Falls Church 15
Phoenix 15
Rio de Janeiro 15
San Jose 15
Timisoara 15
Montreal 14
Norwalk 14
Parma 14
Kent 13
Naples 13
Turku 13
Amsterdam 12
Boston 12
Jersey City 12
Palermo 12
Paris 12
Manchester 11
Nanjing 11
Ho Man Tin 10
Tashkent 10
Abbiategrasso 9
Ankara 9
Buenos Aires 9
Campinas 9
Curitiba 9
Detroit 9
Elk Grove Village 9
Totale 11.687
Salva come PNG Salva come JPEG
Nome #
Terapia antialadosteronica e prevenzione della cardiomiopatia cirrotica 646
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 474
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 436
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 310
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 308
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 290
ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? 283
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 279
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomeres involvement on line pubblication 03-Oct-2012Hepatology- 275
Drugs and acute porphyrias: reasons for a hazardous relationship 275
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 271
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 263
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease 263
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 259
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 253
Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy 251
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? 249
Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes 248
A critical appraisal of the use of ultrasound in hepatic steatosis 243
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 243
Role of Multidrug-Resistance Protein 2 in coproporphyrin transport: results from experimental studies in bile fistula rat models 239
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 239
Nonalcoholic fatty liver disease: Evolving paradigms 237
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma 231
Alcohol and Steatosis: The Japanese Paradox 228
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 225
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy 221
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 221
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 220
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 218
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 216
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 216
From NAFLD in clinical practice to answers from guidelines. 215
Hypothyroidism and nonalcoholic fatty liver disease - A chance association? 215
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease 210
Global multi-stakeholder endorsement of the MAFLD definition 209
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 209
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 201
Association between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis 200
Insulin resistance in advanced liver cirrhosis : the role of liver dysfunction and the “dissociated” effect on glucose versus lipid and amino acid metabolism 198
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 197
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? 194
Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? 192
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? 184
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease 179
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 174
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 172
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 172
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 169
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease 161
The genetic basis of Insulin resistance. A brief review 158
Hyperferritinemia and diagnosis of type 1 Gaucher disease 156
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 153
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 153
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 152
Non-alcoholic fatty liver disease: Diagnosis and investigation 149
Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements 148
Frailty after Liver Transplantation: A Complex Unexplored Issue 141
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 140
Hepatic and extrahepatic malignancies in NAFLD 136
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? 136
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 135
Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? 134
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases 132
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist 132
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry 127
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 126
Colon cancer in a 12-year-old girl with hypertriglyceridemia 125
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 125
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 110
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 107
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 106
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 102
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 99
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 85
Identifying lipid patterns through lipidomic profiling for MASLD detection and severity stratification 73
Lipidomic profiling of MASLD: identifying lipid biomarkers for detection and stratification of disease severity 73
Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease 71
Splenomegaly: Dare to think rare 67
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 67
Mapping the lipid landscape of MASLD: insights into disease progression through lipidomic patterns 65
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 64
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease 64
Diagnosi e storia naturale della steatosi epatica non alcolica. Performance e limiti delle tecniche diagnostiche invasive e non invasive e risultati del follow-up a lungo termine delle cirrosi criptogenetiche. 49
Identifying possible homozygous familial hypercholesterolemia patients: An Italian experts' opinion 38
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group 27
Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study 20
Totale 16.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.163 0 0 0 0 0 162 238 202 120 182 164 95
2021/20221.340 102 118 65 77 83 112 45 53 163 149 247 126
2022/20231.407 133 173 140 123 150 176 27 149 175 17 66 78
2023/2024829 34 53 79 69 162 75 56 82 22 23 56 118
2024/20253.350 82 46 99 191 613 447 319 215 342 201 357 438
2025/20263.852 440 279 583 856 1.108 586 0 0 0 0 0 0
Totale 16.226